Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy–associated C3 glomerulopathy
Sophie Chauvet(Assistance Publique – Hôpitaux de Paris), Frank Bridoux(Université de Poitiers), Bertrand Arnulf(Université Paris Cité), Arnaud François(Université de Rouen Normandie), Laurence Vrigneaud(Générale de Santé), Alexandre Karras(Délégation Paris 5), Guy Touchard(Centre Hospitalier Universitaire de Poitiers), Vincent Javaugue(Université de Poitiers), Moglie Le Quintrec(Centre de Recherche des Cordeliers), Gabriel Choukroun(Centre Hospitalier Universitaire Amiens-Picardie), Dominique Guerrot(Pediatric Nephrology of Alabama), Yahsou Delmas(Centre Hospitalier Universitaire de Bordeaux), Stéphane Burtey(Inserm), Laurent Daniel(Hôpital de la Conception), Véronique Frémeaux-Bacchi(Inserm), Jean Michel Goujon(Université de Poitiers), Florent Petitprez(Inserm), David Ribes(Centre Hospitalier Universitaire de Toulouse), Pierre Ronco(Inserm)
Cited by 183
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
|Annals of Oncology|2015|897
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809